Go Pro
→ Earth's biggest energy source: near Grand Canyon (From Behind the Markets) (Ad)tc pixel Free TCRT Stock Alerts

Alaunos Therapeutics (TCRT) Competitors

Alaunos Therapeutics logo
$1.59 -0.04 (-2.45%)
As of 02:11 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

TCRT vs. BCDA, ANEB, APLT, PLUR, and NRSN

Should you buy Alaunos Therapeutics stock or one of its competitors? Alaunos Therapeutics's main competitors and comparable companies include BioCardia (BCDA), Anebulo Pharmaceuticals (ANEB), Applied Therapeutics (APLT), Pluri (PLUR), and NeuroSense Therapeutics (NRSN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Alaunos Therapeutics compare to BioCardia?

Alaunos Therapeutics (NASDAQ:TCRT) and BioCardia (NASDAQ:BCDA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

Alaunos Therapeutics has higher earnings, but lower revenue than BioCardia. BioCardia is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alaunos TherapeuticsN/AN/A-$4.18M-$1.91N/A
BioCardia$60K278.83-$8.23M-$0.64N/A

In the previous week, BioCardia had 1 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 1 mentions for BioCardia and 0 mentions for Alaunos Therapeutics. BioCardia's average media sentiment score of 1.00 beat Alaunos Therapeutics' score of 0.00 indicating that BioCardia is being referred to more favorably in the news media.

Company Overall Sentiment
Alaunos Therapeutics Neutral
BioCardia Positive

27.7% of Alaunos Therapeutics shares are owned by institutional investors. Comparatively, 20.6% of BioCardia shares are owned by institutional investors. 16.1% of Alaunos Therapeutics shares are owned by company insiders. Comparatively, 17.4% of BioCardia shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

BioCardia has a consensus target price of $25.00, indicating a potential upside of 2,162.44%. Given BioCardia's stronger consensus rating and higher possible upside, analysts plainly believe BioCardia is more favorable than Alaunos Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alaunos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
BioCardia
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Alaunos Therapeutics has a beta of -0.97, suggesting that its share price is 197% less volatile than the broader market. Comparatively, BioCardia has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market.

Alaunos Therapeutics' return on equity of -232.60% beat BioCardia's return on equity.

Company Net Margins Return on Equity Return on Assets
Alaunos TherapeuticsN/A -232.60% -158.99%
BioCardia N/A -569.36%-183.15%

Summary

BioCardia beats Alaunos Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Alaunos Therapeutics compare to Anebulo Pharmaceuticals?

Alaunos Therapeutics (NASDAQ:TCRT) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

27.7% of Alaunos Therapeutics shares are owned by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. 16.1% of Alaunos Therapeutics shares are owned by company insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Alaunos Therapeutics' average media sentiment score of 0.00 equaled Anebulo Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Alaunos Therapeutics Neutral
Anebulo Pharmaceuticals Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alaunos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Anebulo Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Alaunos Therapeutics has a beta of -0.97, meaning that its stock price is 197% less volatile than the broader market. Comparatively, Anebulo Pharmaceuticals has a beta of -1.82, meaning that its stock price is 282% less volatile than the broader market.

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alaunos TherapeuticsN/AN/A-$4.18M-$1.91N/A
Anebulo PharmaceuticalsN/AN/A-$8.48M-$0.19N/A

Anebulo Pharmaceuticals' return on equity of -74.57% beat Alaunos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Alaunos TherapeuticsN/A -232.60% -158.99%
Anebulo Pharmaceuticals N/A -74.57%-68.96%

Summary

Anebulo Pharmaceuticals beats Alaunos Therapeutics on 5 of the 8 factors compared between the two stocks.

How does Alaunos Therapeutics compare to Applied Therapeutics?

Applied Therapeutics (NASDAQ:APLT) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

98.3% of Applied Therapeutics shares are held by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are held by institutional investors. 1.6% of Applied Therapeutics shares are held by insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Applied Therapeutics' average media sentiment score of 0.00 equaled Alaunos Therapeutics'average media sentiment score.

Company Overall Sentiment
Applied Therapeutics Neutral
Alaunos Therapeutics Neutral

Applied Therapeutics has a beta of 2.08, suggesting that its share price is 108% more volatile than the broader market. Comparatively, Alaunos Therapeutics has a beta of -0.97, suggesting that its share price is 197% less volatile than the broader market.

Applied Therapeutics presently has a consensus target price of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Applied Therapeutics is more favorable than Alaunos Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Applied Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Alaunos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Alaunos Therapeutics' return on equity of -232.60% beat Applied Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Applied TherapeuticsN/A -340.84% -175.00%
Alaunos Therapeutics N/A -232.60%-158.99%

Alaunos Therapeutics has lower revenue, but higher earnings than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied Therapeutics$1M15.86-$105.62M-$0.10N/A
Alaunos TherapeuticsN/AN/A-$4.18M-$1.91N/A

Summary

Applied Therapeutics beats Alaunos Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Alaunos Therapeutics compare to Pluri?

Pluri (NASDAQ:PLUR) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

Pluri has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market. Comparatively, Alaunos Therapeutics has a beta of -0.97, meaning that its stock price is 197% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pluri
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Alaunos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Alaunos Therapeutics has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat Alaunos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Pluri-2,162.08% N/A -106.59%
Alaunos Therapeutics N/A -232.60%-158.99%

Alaunos Therapeutics has lower revenue, but higher earnings than Pluri. Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pluri$1.34M11.14-$22.58M-$4.53N/A
Alaunos TherapeuticsN/AN/A-$4.18M-$1.91N/A

In the previous week, Pluri had 1 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 1 mentions for Pluri and 0 mentions for Alaunos Therapeutics. Pluri's average media sentiment score of 0.00 equaled Alaunos Therapeutics'average media sentiment score.

Company Overall Sentiment
Pluri Neutral
Alaunos Therapeutics Neutral

16.6% of Pluri shares are held by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are held by institutional investors. 43.2% of Pluri shares are held by company insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Pluri beats Alaunos Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Alaunos Therapeutics compare to NeuroSense Therapeutics?

NeuroSense Therapeutics (NASDAQ:NRSN) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

NeuroSense Therapeutics' return on equity of 0.00% beat Alaunos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
NeuroSense TherapeuticsN/A N/A N/A
Alaunos Therapeutics N/A -232.60%-158.99%

1.0% of NeuroSense Therapeutics shares are owned by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are owned by institutional investors. 27.4% of NeuroSense Therapeutics shares are owned by company insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

NeuroSense Therapeutics has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market. Comparatively, Alaunos Therapeutics has a beta of -0.97, meaning that its stock price is 197% less volatile than the broader market.

Alaunos Therapeutics is trading at a lower price-to-earnings ratio than NeuroSense Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NeuroSense TherapeuticsN/AN/A-$11.12M-$0.54N/A
Alaunos TherapeuticsN/AN/A-$4.18M-$1.91N/A

In the previous week, NeuroSense Therapeutics had 11 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 11 mentions for NeuroSense Therapeutics and 0 mentions for Alaunos Therapeutics. NeuroSense Therapeutics' average media sentiment score of 0.61 beat Alaunos Therapeutics' score of 0.00 indicating that NeuroSense Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
NeuroSense Therapeutics Positive
Alaunos Therapeutics Neutral

NeuroSense Therapeutics currently has a consensus price target of $8.50, indicating a potential upside of 1,876.74%. Given NeuroSense Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe NeuroSense Therapeutics is more favorable than Alaunos Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NeuroSense Therapeutics
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.67
Alaunos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

NeuroSense Therapeutics beats Alaunos Therapeutics on 12 of the 14 factors compared between the two stocks.

Get Alaunos Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TCRT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TCRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TCRT vs. The Competition

Export
MetricAlaunos TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$4.04M$3.92B$7.07B$12.90B
Dividend YieldN/A3.60%2.54%9.14%
P/E Ratio-0.8312.58271.4925.46
Price / SalesN/A1,369.00625.7592.84
Price / CashN/A45.0028.9235.62
Price / Book1.7116.2110.986.44
Net Income-$4.18M-$22.81M$3.48B$358.18M
7 Day Performance-4.22%1.05%0.38%1.04%
1 Month Performance-20.10%5.62%3.44%-0.44%
1 Year Performance-27.40%48.73%23.27%13.84%

Alaunos Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TCRT
Alaunos Therapeutics
0.3234 of 5 stars		$1.59
-2.5%		N/A-23.8%$4.04MN/AN/A40
BCDA
BioCardia
4.0442 of 5 stars		$1.09
-1.8%		$25.00
+2,193.6%		-47.6%$16.80M$60KN/A40
ANEB
Anebulo Pharmaceuticals
N/A$0.39
+30.0%		N/A-84.9%$15.91MN/AN/A4
APLT
Applied Therapeutics
1.3539 of 5 stars		$0.10
flat		$1.00
+870.9%		N/A$15.86M$1MN/A30
PLUR
Pluri
0.5573 of 5 stars		$1.37
-3.5%		N/A-73.3%$15.83M$1.34MN/A150

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TCRT) was last updated on 9/8/2026 by MarketBeat.com Staff.
From Our Partners
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Gold Explorer Sits Between Barrick’s Nevada Giants
Barrick Mining has spent decades building one of Nevada's richest gold districts, anchored by Fourmile, Goldru...
Wall Street Logic | Sponsoredtc pixel
Earth's biggest energy source: near Grand Canyon
The largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...
Behind the Markets | Sponsoredtc pixel
The 2026 beginners Guide to Gold IRAs
Gold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...
Goldco Direct, LLC | Sponsoredtc pixel
MILLIONAIRE MASTERCLASS INVITE: Altucher
James Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altuche...
Paradigm Press | Sponsoredtc pixel
Under $1… and Wall Street already knows about it
You've seen the crypto market… it's absolutely on fire. And the biggest catalyst could be up next. September 1...
Crypto 101 Media | Sponsoredtc pixel
Why the Treasury still prices gold at 42 dollars an ounce
The U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...
Golden Portfolio | Sponsoredtc pixel
American retirees will miss THIS. Big Banks just moved in.
Central banks spent nearly $130 billion on physical gold last year, on top of $145 billion the year before. Q1...
Cedar Gold Group | Sponsoredtc pixel